Imagine them as the **Insulet** (known for its Omnipod insulin pump) of pain patches, focused on developing innovative transdermal systems for safer drug delivery.

They're a specialized pharmaceutical R&D company, like a focused, early-stage division of **Johnson & Johnson** or **Pfizer**, but solely dedicated to creating advanced, abuse-deterrent drug patches for chronic pain.

• Abuse deterrent fentanyl transdermal system: An extended-release transdermal fentanyl product designed for managing chronic pain while deterring abuse.
• RAMBAM Closed System Transfer Devices: Medical devices for safely transferring substances, developed under a license agreement.

Nutriband Inc. (NTRB) is a clinical-stage pharmaceutical company focused on developing transdermal drug products and medical devices. Based on the provided background information, the company's lead product, an abuse-deterrent fentanyl transdermal system, is currently in development. The RAMBAM Closed System Transfer Devices, developed under a license agreement with Rambam Med-Tech Ltd., are also in development.

As a development-stage company, Nutriband Inc. does not currently have major commercial customers for the sale of its pharmaceutical products or devices, as these products are not yet commercially available on the market. Pharmaceutical development companies typically focus on research, development, clinical trials, and securing regulatory approvals before initiating commercial sales and establishing a customer base.

Gareth Sheridan, Founder and Chief Executive Officer

Gareth Sheridan is an award-winning entrepreneur and the founder of Nutriband Inc.. He founded Nutriband Ltd. in Dublin in 2012 and subsequently established Nutriband Inc. in the United States. Sheridan led the company to a Nasdaq listing in 2021. In addition to his role at Nutriband, he is also an independent consultant for several companies and a private investor. He returned to the CEO position in October 2025 after a brief leave.

Gerald Goodman, Chief Financial Officer

Gerald Goodman has served as Nutriband's chief accounting officer since July 31, 2018, and became the Director of Finance/CFO on September 1, 2020.

Serguei Melnik, Founder and President

Serguei Melnik is a founder of Nutriband Inc. and currently serves as its President. He has been involved in general business consulting for companies in the U.S. financial markets. Mr. Melnik temporarily took over as interim CEO from August 10 to October 27, 2025.

Dr. Alan Smith, Chief Operating Officer and President of 4P Therapeutics

Dr. Alan Smith serves as the Chief Operating Officer of Nutriband and President of its subsidiary, 4P Therapeutics. Nutriband acquired 4P Therapeutics in 2018, an acquisition that brought the proprietary AVERSA™ abuse-deterrent transdermal technology to the company.

Dr. Jeff Patrick, Chief Scientific Officer

Dr. Jeff Patrick is the Chief Scientific Officer of Nutriband Inc. He also currently serves as the Director of the Drug Development Institute at the Ohio State University Comprehensive Cancer Center.

The key risks to Nutriband Inc. (NTRB) primarily revolve around the challenging landscape of pharmaceutical development and commercialization.

1. Regulatory Approval and Commercialization of AVERSA Fentanyl: Nutriband's lead product, AVERSA Fentanyl, an abuse-deterrent transdermal fentanyl system, is currently under development, and its future success is contingent on obtaining regulatory approval from the FDA. The company needs to successfully complete clinical testing, secure patent protection for its abuse-deterrent technology, and obtain the necessary financing to advance through the regulatory process and ultimately market the product in the United States and other countries. Despite ongoing progress, including meetings with the FDA and a targeted NDA submission, there are inherent uncertainties and significant challenges associated with pharmaceutical product development and regulatory approval.

2. Financial Performance and Funding: Nutriband has consistently incurred substantial net losses, indicating ongoing operational challenges despite some revenue growth. The company experiences increased cash burn from operations due to significant development costs, necessitating a reliance on external funding sources for its product initiatives. While Nutriband demonstrates strong liquidity and a low debt-to-equity ratio, its profitability metrics, such as negative operating and net margins, highlight difficulties in generating returns for shareholders. The need for continuous capital infusion to support product development and the potential implications of financing strategies, such as preferred stock dividends tied to future product approvals, underscore financial stability as a key risk.

3. Competition and Market Acceptance: Nutriband operates in competitive markets for both its transdermal pharmaceutical products and its licensed Closed System Transfer Devices (CSTDs). The success of AVERSA Fentanyl depends on its ability to gain market acceptance against existing pain management solutions, even with its abuse-deterrent properties. For the RAMBAM Closed System Transfer Devices, the market includes established players, and challenges such as high integration costs and limited compatibility with certain medications could hinder adoption. The general competitive landscape and the ability to effectively market newly developed products are frequently cited risks in the company's forward-looking statements.

Nutriband Inc. operates in two primary markets with its key products:

Abuse-Deterrent Fentanyl Transdermal System (AVERSA™ Fentanyl)
Nutriband's lead product, AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system, has the potential to reach peak annual U.S. sales of $80 million to $200 million. This product is designed to be the world's first abuse-deterrent opioid patch. The broader global transdermal patches market was valued at approximately USD 7.84 billion in 2024 and is projected to grow to USD 11.50 billion by 2032. Within this, the fentanyl transdermal patch segment held the largest market share, around 44%, in 2024. The global fentanyl market size is expected to be valued at US$2.5 billion in 2026 and reach US$3.5 billion by 2033.

RAMBAM Closed System Transfer Devices (CSTD)
The global market for Closed System Transfer Devices (CSTD) is estimated to be USD 1.62 billion in 2026, with projections indicating growth to USD 2.97 billion by 2031, at a compound annual growth rate (CAGR) of 12.98% from 2026 to 2031. Another estimate placed the global CSTD market at US$1.49 billion in 2025, with a projected growth to US$2.09 billion by 2030 at a CAGR of 7.0%. North America is a significant region within this market, holding a 42.84% share in 2025 and dominating with a 43.5% revenue share in 2024. The North American CSTD market is expected to reach US$2.5 billion by 2029, growing at a CAGR of 14.5% during the forecast period.

Nutriband Inc. (NASDAQ: NTRB) is poised for future revenue growth over the next two to three years, driven by the anticipated commercialization of its lead pharmaceutical products, expansion of its abuse-deterrent technology platform, and continued growth in its contract manufacturing services.

Here are the key drivers of future revenue growth:

1. Commercialization of AVERSA Fentanyl: Nutriband's lead product, AVERSA Fentanyl, an abuse-deterrent fentanyl transdermal system, is a primary growth driver. The company has made significant progress, targeting a New Drug Application (NDA) submission in 2025. AVERSA Fentanyl is being developed via a 505(b)(2) regulatory pathway, requiring only a single Phase 1 Human Abuse Potential study, which is expected to expedite the approval process. Market analysis projects potential peak annual sales for AVERSA Fentanyl to range between $80 million and $200 million. Nutriband has partnered with Kindeva Drug Delivery for commercial manufacturing scale-up, further positioning it for market entry.
2. Advancement of AVERSA Buprenorphine and Pipeline Expansion: Beyond AVERSA Fentanyl, Nutriband is advancing AVERSA Buprenorphine, another abuse-deterrent transdermal application, which is projected to achieve peak annual sales of up to $130 million upon approval. The company also plans to expand its AVERSA platform to other high-potential transdermal applications, including methylphenidate, aiming to establish a new safety standard for opioids and other drugs of abuse.
3. Growth in Kinesiology Tape Contract Manufacturing: The company's Pocono Pharma subsidiary is continually expanding its kinesiology tape contract manufacturing services. This segment has already demonstrated strong performance, with Nutriband reporting significant year-over-year revenue increases from these services. Pocono-manufactured products are increasingly available in major retail chains such as Target, Walmart, Walgreens, and CVS. Additionally, Nutriband has an exclusive supplier agreement with Fit For Life Group, further bolstering this revenue stream.

Share Repurchases

• Nutriband Inc. authorized a share repurchase program to buy back up to $1,000,000 of its common stock, announced on September 16, 2024.

Share Issuance

• In July 2025, Nutriband issued a 25% Preferred Stock dividend to existing shareholders, with one preferred share granted for every four shares of common stock held, convertible to common stock upon FDA approval of AVERSA Fentanyl.
• Warrants issued during the company's October 1, 2021, IPO, with a strike price of $6.43 and totaling 91,0904, are set to expire on October 1, 2026, representing a potential capital inflow of $5,856,112 if all are exercised.
• Shareholders approved an amendment on January 24, 2026, to increase the number of authorized preferred shares from 10,000,000 to 20,000,000.

Outbound Investments

• Nutriband entered an agreement to sell a 90% interest in its subsidiary, Pocono Pharmaceutical, to EarthVision Bio for $5 million in December 2025.
• The proceeds from the Pocono Pharmaceutical sale are intended to fund the continued development of AVERSA Fentanyl.

Capital Expenditures

• Capital expenditures for the last 12 months (prior to March 2026) were -$5,324.
• The company reported $0 in capital expenditures in Q3 2026.